Log In
BCIQ
Print this Print this
 

ubrogepant (MK-1602)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOral calcitonin gene-related peptide (CGRP) receptor antagonist
Molecular Target Calcitonin gene-related peptide (CGRP) receptor
Mechanism of ActionCalcitonin gene-related peptide (CGRP) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat migraine
Regulatory Designation
PartnerAllergan plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$250.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/07/2015

Undisclosed

$250.0M

Undisclosed

Get a free BioCentury trial today